CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights.
Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺导管腺癌（PDAC）是胰腺癌最常见的类型，也是发达国家第四大常见死因。尽管切除联合辅助化疗或新辅助化疗后生存率有所提高，但仍有高比例患者在切除后前2年内出现复发。免疫治疗旨在改善抗肿瘤免疫反应并降低毒性，与化疗相比提供了一种更具特异性、靶向性的治疗，并已被证明是许多实体瘤的有效治疗工具。在本研究中，我们介绍了PDAC治疗的最新进展，即在新辅助和辅助治疗背景下，将免疫治疗与化疗和/或放疗等其他干预措施相结合。此外，我们概述了肿瘤微环境作为免疫治疗疗效关键屏障的作用，并探讨了免疫治疗生物标志物如何用于检测免疫治疗的反应。
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and fourth most common cause of death in developed countries. Despite improved survival rates after resection combined with adjuvant chemotherapy or neoadjuvant chemotherapy, recurrence still occurs in a high percentage of patients within the first 2 years after resection.
Immunotherapy aims to improve antitumor immune responses and reduce toxicity providing a more specific, targeted therapy compared to chemotherapy and has been proved an efficient therapeutic tool for many solid tumors. In this work, we present the latest advances in PDAC treatment using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation both at neoadjuvant and adjuvant setting.
Moreover, we outline the role of the tumor microenvironment as a key barrier to immunotherapy efficacy and examine how immunotherapy biomarkers may be used to detect immunotherapy's response.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
